0

AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?

What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met – by both sides? After 10 years of AMNOG first conclusions and recommendations for changes can be made.

 

 

MAP – Market Access Podcast, is the first and only bi-weekly market access podcast provided by MArS. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

Episode 21 – July 1, 2022

Undine McEvoy

Leave a Reply

Your email address will not be published.